Edaravone Dexborneol via SLC33A1 Modulates Microglial Lipid Droplet Homeostasis to Suppress Neuronal Necroptosis in Acute Ischemic Stroke
CNS Neuroscience & Therapeutics · 2026-11 · 32 (11)
DOI: 10.1002/cns.71257 ↗Kurz gefasst
Fachartikel in der Zeitschrift CNS Neuroscience & Therapeutics, online erschienen am 17.11.2026. Verfasst von Zhou Zhou und 14 weiteren Autor:innen. Die Arbeit nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Themen: Schlaganfall
Abstract (Originalsprache)
Aims
Acute ischemic stroke (AIS) remains a leading cause of mortality and disability worldwide, underscoring the need for effective neuroprotective therapies. Edaravone Dexborneol, a novel compound consisting of edaravone and (+)‐borneol, showed superior efficacy compared with edaravone alone in a Phase III clinical trial; however, its effects on lipid metabolism in AIS remain unclear. This study aimed to elucidate the neuroprotective mechanism of Edaravone Dexborneol, with a focus on microglial lipid droplet homeostasis.
Methods
A mouse transient middle cerebral artery occlusion (tMCAO) model and in vitro ischemic models were used to evaluate the neuroprotective effects of Edaravone Dexborneol. Cerebral infarct volume and neurological function were assessed, and metabolomic and proteomic analyses were performed to identify potential mechanisms. Immunofluorescence and molecular assays were used to examine microglial lipid droplet accumulation, autophagy, inflammatory responses, neuronal necroptosis, and the involvement of SLC33A1.
Results
Edaravone Dexborneol reduced cerebral infarct volume and improved neurological function more effectively than edaravone or (+)‐borneol alone. Metabolomic analysis indicated that its protective effects were mainly associated with pathways related to lipid droplet homeostasis. Immunofluorescence showed that Edaravone Dexborneol more effectively reduced microglial lipid droplet accumulation than either monotherapy. Proteomic analysis further suggested the involvement of autophagy‐ and necroptosis‐related pathways. Notably, Edaravone Dexborneol significantly upregulated the transmembrane acetyl‐CoA transporter SLC33A1, thereby regulating microglial autophagy–lipid droplet homeostasis. This was associated with reduced abnormal lipid accumulation, suppressed M1‐like microglial polarization, decreased pro‐inflammatory cytokine release, and attenuated neuronal necroptosis after ischemia.
Conclusions
Edaravone Dexborneol exerts neuroprotective effects in AIS by restoring microglial lipid droplet homeostasis and alleviating inflammation‐driven neuronal necroptosis via SLC33A1. These findings provide a mechanistic basis for its therapeutic benefit in AIS and identify SLC33A1 as a potential therapeutic target.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Zhou, Z., Yan, Y., Liu, L., Zhou, Y., Yao, Q., Zhao, M., Wang, X., Yao, D., Pei, G., Lv, X., Bai, G., Meng, C., Wang, B., Guo, X., & Liu, X. (2026). Edaravone Dexborneol via SLC33A1 Modulates Microglial Lipid Droplet Homeostasis to Suppress Neuronal Necroptosis in Acute Ischemic Stroke. CNS Neuroscience & Therapeutics, 32(11). https://doi.org/10.1002/cns.71257
Vancouver
Zhou Z, Yan Y, Liu L, Zhou Y, Yao Q, Zhao M, et al. Edaravone Dexborneol via SLC33A1 Modulates Microglial Lipid Droplet Homeostasis to Suppress Neuronal Necroptosis in Acute Ischemic Stroke. CNS Neuroscience & Therapeutics. 2026;32(11). doi:10.1002/cns.71257
BibTeX
@article{Zhou2026,
author = {Zhou, Zhou and Yan, Yan and Liu, Lijuan and Zhou, Yicong and Yao, Qiang and Zhao, Minghan and Wang, Xuelin and Yao, Dongjing and Pei, Guanhui and Lv, Xin and Bai, Ge and Meng, Chaoyue and Wang, Binbin and Guo, Xin and Liu, Xiaoyun},
title = {Edaravone Dexborneol via SLC33A1 Modulates Microglial Lipid Droplet Homeostasis to Suppress Neuronal Necroptosis in Acute Ischemic Stroke},
journal = {CNS Neuroscience & Therapeutics},
year = {2026},
volume = {32},
number = {11},
doi = {10.1002/cns.71257}
}
EUVIMED